

EFFECTIVE FIRST-LINE SSRI THERAPY FOR OCD...

EMERGING FROM THE PROFOUND ANXIETY OF OCD

RITUALS

OBSSESSIONS
COMPULSIONS

REPETITIVE
THOUGHTS



Low incidence of agitation


- 2% vs 1% for placebo¹

Low incidence of sexual dysfunction¹

- LUVOX[®] Tablets vs placebo*: decreased libido 2% vs 1%; delayed ejaculation 8% vs 1%; anorgasmia 2% vs 0%; impotence 2% vs 1%

Favorable tolerability profile

- Relatively low incidence of anticholinergic side effects in controlled trials of OCD and depression. LUVOX[®] Tablets vs placebo: dizziness 11% vs 6%; constipation 10% vs 8%; dry mouth 14% vs 10%¹
- For adults, the most commonly observed adverse events compared to placebo were somnolence 22% vs 8%; insomnia 21% vs 10%; nervousness 12% vs 5%; nausea 40% vs 14%; asthenia 14% vs 6%¹
- Adverse events in children and adolescents were similar to those observed in adult studies. The most commonly observed adverse events compared to placebo were: agitation 12% vs 3%; hyperkinesia 12% vs 3%; depression 5% vs 0%; dysmenorrhea 7% vs 3%; flatulence 5% vs 0%; rash 7% vs 3%
- Concomitant use of LUVOX[®] Tablets and monoamine oxidase inhibitors is not recommended¹



AVAILABLE IN 25-mg TABLETS

LUVOX[®]
fluvoxamine maleate
25 mg TABLETS 50 mg & 100 mg SCORED TABLETS

*Parameters occurring $\geq 1\%$ with fluvoxamine maleate.

Please see brief summary of prescribing information on adjacent page.

First-line SSRI therapy for obsessions and compulsions